A new group of negative cell cycle regulators has been described whose members act as cyclin-dependent kinase inhibitors (CKIs) (1) (2) (3) . CKI family members have been subdivided into two groups on the basis of sequence homology. The first CKI member to be characterized was p21 (also known as WAF1, Cip1, or Sdi1) (4) (5) (6) . The other members of this group are p27/Kip1 (7) (8) (9) and p57/ Kip2 (10, 11) . The other CKI subgroup includes four members: p16/INK4A/MTS1/ CDKN2A (12, 13) , p15/INK4B/MTS2/ CDKN2B (14) , p18/INK4C (15) , and p19/INK4D (16) . The INK4A and INK4B genes map to the short arm of chromosome 9 (9p21), where they are found in tandem, spanning a region of approximately 80 kilobases (kb). The INK4A gene was initially described as encoding a 148-amino-acid protein of relative molecular mass (M r ) 15 845, termed p16 (12, 13) . The INK4B gene encodes a protein of 137 amino-acid residues with M r 14 700, known as p15 (14) . The p16 and p15 proteins form binary complexes exclusively with the cyclin-dependent kinases Cdk4 and Cdk6, inhibiting their function and, by doing so, inhibiting pRB phosphorylation during G 1 . Additional complexity results from the presence of a second INK4A product, which has been termed p19 ARF (ARF stands for alternative reading frame) (17) (18) (19) (20) . The p19 ARF product has been recently shown to interact with Mdm2, a protein that binds to the p53 protein, and to block the Mdm2-induced degradation and transactivational silencing of p53 (21, 22) .
Soft tissue sarcomas have been classified histogenetically according to their morphologic resemblance to normal cognate tissues. The prognosis of patients with soft tissue sarcomas has traditionally been determined by clinical and histopathologic features of the tumor such as grade, size, and depth. The histologic type of a patient's sarcoma has not been shown, however, to be a consistent independent prognostic factor. Recent advances in the recognition and understanding of molecular genetic events occurring in the pathogenesis of human sarcomas have resulted in attempts to define new diagnostic and prognostic markers. Several sarcomas have been found to be characterized by recurrent chromosomal aberrations, mainly translocations, that are specific to particular histologic types. One example is the reciprocal translocation t(9;22) (q22;q12) that is reported in most extraskeletal myxoid chondrosarcomas (23) . Deletions in 9p12-p22 occur nonrandomly in some soft tissue tumors (24) . The INK4A and INK4B genes have been found to be mutated in many tumor cell lines and several primary tumors (13, (25) (26) (27) (28) (29) . In addition, methylation of the 5Ј CpG island located in the promoter region of the p16 gene has been reported to be a frequent mechanism of that gene's inactivation in certain neoplasms (30, 31) . More recently, independent studies reported the targeted deletion of the Ink4a and specific loci within p19 ARF exon 1␤ in murine models (32, 33) . Both Ink4a-and p19 ARFdeficient mice were viable, but they developed spontaneous tumors at an early age. Soft tissue sarcomas were one of the most common tumor types observed in these knockout mice. The evidence that INK4A encodes two products that have an impact on different tumor suppressors-p16 acting through pRB and p19 ARF preventing Mdm2 neutralization of p53-positions this gene at the nexus of the two most critical tumor suppressor pathways controlling neoplasia (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) .
The present study was undertaken to better delineate the frequency and potential clinical relevance of INK4A and INK4B gene alterations in a wellcharacterized cohort of adult soft tissue sarcomas. We have also evaluated alterations of pRB, p53, and Mdm2 in the same cohort of sarcomas and analyzed their association with INK4A and INK4B mutations.
MATERIALS AND METHODS

Tissue and Patient Characteristics
Tumors from 46 patients with adult soft tissue sarcomas were analyzed. The tumor specimens corresponded to 12 liposarcomas, 11 leiomyosarcomas, seven malignant fibrous histiocytomas, five malignant peripheral nerve sheath tumors, four fibrosarcomas, four synovial sarcomas, one rhabdomyosarcoma, one desmoid tumor, and one unclassified sarcoma. Twenty-six tumors were confined to the extremities (19 primary, four recurrent, and three metastatic), four tumors were retroperitoneal (one primary and three recurrent), and 16 tumors were localized in other sites including the lung, liver, stomach, rectum, small bowel, prostate, and pelvis (seven primary, one recurrent, and eight metastatic). Ten tumors were classified as low grade; 36 were classified as high grade. In nine cases, the tumor size was less than or equal to 5 cm; in 37 cases, it was greater than 5 cm. Samples were embedded in cryopreservation compound O.C.T. (i.e., optimal cutting temperature compound; Miles Laboratories, Elkhart, IN), snap-frozen in isopentane that had been precooled in liquid nitrogen, and stored at −70°C. Representative hematoxylin-eosin-stained sections of each frozen block were examined microscopically to confirm the presence of tumor, and only lesions with more than 50% neoplastic cells were included in the study. Normal tissues were obtained from all patients, either from a tumor-free area, such as skeletal muscle, or from peripheral blood.
Southern Blotting Analysis
A 0.5-kb complementary DNA (cDNA) fragment containing human p16 sequences and a 2-kb cDNA fragment containing human p15 sequences were used as probes to assess deletion and rearrangement of the INK4A and INK4B genes, respectively. A cDNA fragment containing glyceraldehyde phosphate dehydrogenase (GAPDH) sequences was used as a control. In general, Southern blot analysis was performed as described previously (26) . Briefly, DNA was extracted by use of a non-organic method (Oncor, Inc., Gaithersburg, MD) from paired normal tissue and tumor samples. Extracted DNA (7.5-g aliquots) was digested with TaqI restriction endonuclease, and the digested DNA was subjected to electrophoresis in 0.7% agarose gels and blotted onto nylon membranes. The membranes were prehybridized with Hybrisol I (Oncor, Inc.) at 42°C for 1 hour and then incubated overnight at 42-43°C with probes labeled to high specific activity with the use of [␣-32 P]deoxycytidine triphosphate (dCTP) (Dupont NEN Research Products, Boston, MA). Hybridized membranes were washed at high stringency with 0.1× standard saline citrate-0.1% sodium dodecyl sulfate at −70°C and autoradiographed with the use of intensifying screens at −70°C for 24-72 hours. Densitometric evaluation of autoradiographic band intensities was performed by use of an Ultrascan XL Laser Densitometer (Pharmacia LKB Biotechnology, Piscataway, NJ). Relative amounts of a given CKI gene present were determined by the comparison of gene-specific hybridization signals with those obtained with the use of the control probe (26) .
In addition, a human MDM2 cDNA fragment probe of 1.6 kb, pHDM (EcoRI), was used in Southern blots to assess gene amplification, in conjunction with a ␤-actin probe (EcoRI) used as control, following protocols previously described (34) .
Polymerase Chain ReactionSingle-Strand Conformation Polymorphism and Multiplex Polymerase Chain Reaction Analyses
Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) assays were performed in a subset of the tumors following protocols described previously (26) (see below for details) . The primers used to amplify the INK4A and INK4B genes can be summarized as follows: 1) p16, exon 1␣-5Ј GGG AGC AGC ATG GAG CCG 3Ј (F) and 5Ј AGT CGC CCG CCA TCC CCT (R); 2) p16, exon 2-5Ј GGA AAT TGG AAA CTG GAA GC 3Ј (42F), 5Ј TCT GAG CTT TGG AAG CTC T 3Ј (551R), and 5Ј GGA TAG AGA ACT CAA GAA GG 3Ј (35F); 3) p19 ARF , exon 1␤ (fragment 1, 439 bp)-5Ј TCC CAG TCT GCA GTT AAG G 3Ј (F) and 5Ј GTC TAA GTC GTT GTA ACC CG 3Ј (R); 4) p19 ARF , exon 1␤ (fragment 2, 160 bp)-5Ј AAC ATG GTG CGC AGG TTC 3Ј (F) and 5Ј AGT AGC ATC AGC ACG AGG G 3Ј (R); 5) p15, exon 1-5Ј AAG AGT GTC GTT AAG TTT ACG 3Ј (51F) and 5Ј ACA TCG GCG ATC TAG GTT CCA 3Ј (32F); and 6) p15, exon 2-5Ј GGC CGG CAT CTC CCA TAC CTG 3Ј (41F) and 5Ј TGT GGG CGG CTG GGG AAC CTG 3Ј (365R). DNA was amplified in 30 cycles of PCR by use of a thermal cycler (The Perkin-Elmer Corp., Foster City, CA) and conditions that have been described previously (26) . Briefly, these PCR reactions were performed in 10-L volumes containing 80-100 ng of template DNA, 2. 2 , 100 M deoxynucleotide triphosphates (dNTPs), 3% dimethyl sulfoxide (DMSO), 0.6 U of TaqI polymerase, and 1× PCR buffer (Promega, Madison, WI). The annealing temperatures ranged from 55°C to 68°C. For SSCP analysis of exon 2 of the INK4A, 4 L of a PCR product was digested with the restriction enzyme BanII. For the SSCP analysis of the exon 1␤ (fragment 1) of the p19 ARF , the PCR product was digested with NarI and EheI restriction enzymes for 2 hours at 37°C. Both digested and nondigested products were analyzed by SSCP. The PCR products were denatured and loaded onto a nondenaturing 8% polyacrylamide gel containing 10% glycerol and subjected to electrophoresis at room temperature for 12-16 hours at 10-12 W. After electrophoresis, the gels were dried and exposed to x-ray film at −70°C for [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] hours.
An independent DNA amplification was performed for the comparative multiplex PCR assay. A simultaneous amplification of genomic DNA was performed by use of two sets of primers, one to the target gene sequence under study and the other to an internal control gene sequence. The GAPDH and the androgen receptor (ANDRR) genes were utilized as internal controls for DNA quality and loading. The primers used for the GAPDH and ANDRR genes can be summarized as follows: 1) GAPDH-5Ј TGG TAT CGT GGA AGG ACT CAT GAC 3Ј (F) and 5Ј ATG CCA GTG AGC TTC CCG TTC AGC 3Ј (R) (fragment: 189 bp); 2) ANDRR-5Ј GTG CGC GAA GTG ATC CAG AA 3Ј (F) and 5Ј TCT GGG ACG CAA CCT CTC TC 3Ј (fragment: 296 bp). The concentration and the quality of each DNA template were determined by densitometry and by comparison with mass markers on an agarose gel (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD). Each PCR reaction tube contained 50-100 ng of genomic DNA, 1× PCR buffer (Promega), 3.2 mM MgCl 2 , 130 M dNTPs, 5% DMSO, 0.4 M of INK4A exon 1␤ primer, 0.4 M of each ANDRR primer, 0.5 U Taq polymerase (Promega), and 1 Ci of [␣-33 P]dCTP. Samples were preheated at 95°C for 5 minutes and amplified for 25 cycles with annealing temperatures ranging from 59°C to 53°C, followed by an extension at 72°C for 10 minutes. PCR products were run in nondenaturing 8% acrylamide gels at 40-45 W for 3-4 hours. Gels were dried and exposed to sensitive film and to a phosphoimage plate. The sensitized plate was scanned by a phosphoimager (Bac 1000-Mac; Bio Imaging System Fujix, Fuji, Japan). The presence of the exon 1␤ was expressed as the following ratio: (target-band signal)/(control-band signal). All experiments were conducted at least twice, and samples were analyzed by use of primers directed to a smaller exon 1␤ fragment (fragment 2; see above) to rule out false-negative results due to partial DNA degradation. For the establishment of potential p19 ARF allelic losses in the tumor DNA samples, tumor DNA samples lacking p16 and p15 genes by Southern blot analysis were used as control DNAs, validating the quantitative nature of the multiplex PCR method. Briefly, varying mixtures of tumor DNA and normal genomic DNA were coamplified. These tumor-to-normal DNA mixtures represented a range of the p19 ARF exon 1␤ content, varying from 0% of target (tumor-sample control) to 100% of target (normal DNA counterpart). Samples presenting less than 10% of the control signal were considered to be homozygously deleted, and those presenting less than 60% were considered to be heterozygously deleted for exon 1␤.
In addition, a TP53 mutation analysis of exons 4-8 was conducted by PCR-SSCP and sequencing, following protocols previously described (34) .
Analysis of Methylation
The methylation status of the 5Ј CpG island in the promoter region of the p16 gene was determined with the CpG Wiz™ p16 Methylation Kit (Oncor, Inc.). Briefly, 0.5-1 g of DNA was denatured with 3 M NaOH at 50°C for 10 minutes and treated with sodium bisulfite following the manufacturer's protocol. After completion of the DNA modification, the DNA was purified by precipitation. The dissolved DNA was amplified by PCR, utilizing primers specific for the methylated (M) or unmethylated (U) sequences. A 2-to 3-L aliquot of template (corresponding to treated DNA, positive control for methylated DNA, positive control for unmethylated sequences, and distilled water as negative control) was amplified in the presence of 10× Universal PCR Buffer, 2.5 mM dNTP mix, U or M primers, and AmpliTaq Gold™ (The PerkinElmer Corp.), under the following conditions: preheating (95°C, 12 minutes), followed by 35 cycles (95°C, 45 seconds; 66°C, 45 second; and 72°C, 1 minute). The PCR product was analyzed on a 2% agarose gel. The presence of DNA methylation was determined by the identification of a 145-bp fragment in those samples amplified with the M primers. All the cases were evaluated for the presence of an unmethylated specific fragment (154 bp), which served as internal control for the quality of the treated DNA.
Monoclonal Antibodies and Immunohistochemistry
Well-characterized mouse monoclonal antibodies to p53, Mdm2, and pRB proteins were used for this study. Antibody PAbl80l reacts with both wild-type and mutant p53 products, recognizing a denaturation-resistant epitope that expands between amino acids 32 to 79 (34) . A mouse monoclonal antibody identifying an epitope in the central portion of Mdm2, clone 2A10, was also used in the study (34) . Antibody Rb-PMG3-245 was generated by immunizing mice with the TrpE/Rb fusion protein, and it has been shown to specifically recognize the 110-kd RB gene product (35) . A class-matched mouse monoclonal antibody (MIgS-Kp-1; Pharmingen, San Diego, CA) was used at the same working concentrations as the primary antibodies, serving as a negative control.
Immunohistochemistry was performed on 5-m frozen sections by use of the avidin-biotin complex immunoperoxidase technique (34, 35) . Sections were incubated with appropriately diluted primary antibodies (PAbl80l-200 ng/mL; 2A10-1 : 1000 dilution from tissue culture supernatant; Rb-PMG3-245-10 g/mL) for 1 hour at room temperature. Secondary, biotinylated horse anti-mouse antibodies (Vector Laboratories, Inc., Burlingame, CA) were used at 1 : 100 dilution, and avidin-biotin peroxidase complexes (Vector Laboratories, Inc.) were used at a dilution of 1 : 25. Diaminobenzidine was used as the final chromogen (0.06%), and hematoxylin was used as the nuclear counterstain.
Immunohistochemical evaluation was performed by scoring the estimated percentage of tumor cells that showed nuclear staining. Nuclear immunoreactivities of p53 and Mdm2 were considered positive when at least 20% of the tumor cells showed nuclear staining (34) . pRB was considered undetectable when nuclear staining was observed in normal endothelial cell and/or inflammatory elements but not in tumor cells (35) . The immunohistochemical analysis was done in a blinded fashion (i.e., without knowledge of the molecular data or clinical information).
Statistical Analyses
Patients were categorized according to the stage, grade, histologic type, site, and presentation of their tumors as defined in Table 1 
The FREQ procedure in SAS was used (37) . In the analysis of disease-specific survival, patients who died of soft tissue sarcomas were classified as dead of disease, whereas patients who were still alive, had died of unrelated causes, or were lost to follow-up during the study period were coded as censored. Survival time was defined as the time from date of surgery to the endpoint (death or censoring). Disease-specific survivals were evaluated with the use of the Kaplan-Meier method (38) and logrank test (39) . The LIFETEST procedure in SAS was used for analysis of these data (37) . Proportional hazards analysis was used to obtain maximum likelihood estimates of relative risks (RRs) and their 95% confidence intervals (CIs) in a multivariate analysis (40, 41) . The data were consistent with the assumptions of Cox proportional hazards analysis.
RESULTS
Forty-six paired samples of normal and tumor DNA were available for Southern blot analysis of the INK4A and INK4B genes. Fig. 1 illustrates normal and altered patterns of bands obtained through Southern blot analysis. Of 46 sarcomas, we found that seven (15%) had abnormalities in the INK4A and INK4B genes, including total or partial allelic deletions of both genes and a rearrangement of INK4A. Tumor types exhibiting these abnormalities were represented by three malignant peripheral nerve sheath tumors, two leiomyosarcomas, one malignant fibrous histiocytoma, and one liposarcoma. Homozygous deletion (i.e., loss of both alleles) of the INK4A gene was detected in five tumors (Fig. 1, D) , and hemizygous deletion (i.e., loss of one allele) was observed in one tumor (Fig. 1, C ). An abnormal pattern of INK4A bands was observed in one tumor (Fig. 1, B) ; the control probe did not show any abnormality in this DNA, suggesting a possible gene rearrangement. All of the tumors that exhibited homozygous deletions of the INK4A gene also presented with homozygous deletion of the INK4B gene (Fig. 1, D) . The single case exhibiting partial loss or loss of heterozygosity (LOH) of the INK4A gene also displayed LOH of the INK4B gene (Fig. 1, C) . The single case that displayed an abnormal pattern of bands for INK4A appeared to be normal for the INK4B gene (Fig. 1, B) . The analysis of PCR-SSCP data for all of the exons screened-including the exons 1␣, 1␤, and 2 of the INK4A gene, as well as the exons 1 and 2 of the INK4B gene-did not reveal altered fragment mobility shifts (data not shown). In cases where no signal was obtained after amplification by PCR, homozygous deletion of the INK4A and INK4B genes was confirmed by Southern blot analysis. The comparative multiplex-PCR data for exon 1␤ of INK4A, corresponding to p19 ARF , revealed that losses of this locus occurred in six cases. The five tumors displaying homozygous deletion of p19 ARF (i.e., INK4A exon 1␤) showed concomitant homozygous deletions of the remaining exons of the INK4A gene, as well as of the INK4B gene (Fig. 2) . Similarly, the single tumor that exhibited partial loss of p19 ARF exon 1␤ also showed LOH of the INK4A gene and of the INK4B gene.
Samples that retained one or more alleles of the INK4A gene were analyzed for the methylation status of the 5Ј CpG island. Methylated and unmethylated control DNAs showed the corresponding methylated-and unmethylated-specific fragments, respectively. All of the 33 tumors analyzed revealed the absence of the methylation-specific fragment.
The overall frequency of alterations in this cohort of soft tissue sarcomas was approximately 15% for the INK4A and INK4B genes, with theses changes affecting high-grade sarcomas exclusively. Statistically significant associations were observed between INK4A and INK4B gene deletions and poor survival (P ‫ס‬ .036; Fig. 3, A) and between INK4A/INK4B gene alterations and poor survival (P ‫ס‬ .005; Fig. 3, B) . In a multivariate analysis that used the Cox proportional hazards model, the calculated RRs after controlling for tumor grade and size were 2.29 (95% CI ‫ס‬ 0.80-6.58; P ‫ס‬ .12) for INK4A/INK4B deletions and 2.98 (95% CI ‫ס‬ 1.09-8.18; P ‫ס‬ .03) for INK4A/B alterations. None of the RRs, calculated from the proportional hazards model, for either tumor grade or size were statistically significant (data not shown).
The tumors were also analyzed for the presence of TP53 mutations (exons [4] [5] [6] [7] [8] and MDM2 amplifications. In addition, altered patterns of p53, Mdm2, and pRB protein expression were further characterized. Table 1 summarizes the results obtained from the analyses of the INK4A and INK4B status with regard to TP53 and MDM2 alterations, as well as with regard to p53, Mdm2, and pRB protein expression phenotype. Sixteen (35%) of the 46 sarcomas showed TP53 mutations and/or p53 nuclear overexpression (data not 
DISCUSSION
We report an overall frequency of deletions and rearrangements for the INK4A and INK4B genes in adult soft tissue sarcomas of 15%. We did not detect any point mutations either in exons 1␣ and 2 of the p16 gene (97.5% of the total coding sequence) or in exons 1 and 2 of the p15 gene (75% of the total coding sequence). Similarly, we did not identify a case in which the p16 promoter underwent de novo methylation. The additional complexity that results from the presence of a second INK4A-encoded gene product, p19
ARF , was also taken into consideration in this study. The analysis of the INK4A-alternative reading frame (exons 1␤ and 2, 100% of the total coding sequence) revealed the absence of tumor-specific point mutations. However, five homozy- Fig. 3 . Survival curves for patients with soft tissue sarcomas. Disease-specific survival was evaluated with the use of the Kaplan-Meier method, and curves were compared with the logrank test. All P values are two-sided and considered statistically significant if less than .05. A) The probability of overall survival was significantly higher in sarcoma patients with normal INK4A and INK4B genes than in those with deletions in these genes (P ‫ס‬ .036). For patients whose tumors did not have INK4A and INK4B deletions, 95% confidence intervals (CIs) for the proportion surviving at 11 and 48 months were 0.68-0.93 and 0.44-0.77, respectively; for patients with tumors exhibiting such deletions, the 95% CIs at 11 and 47 months were 0.30-0.97 and 0.03-0.70, respectively. B) The probability of overall survival was significantly higher in sarcoma patients with normal INK4A and INK4B genes than in those with alterations in these genes (P ‫ס‬ .005). For patients whose tumors did not have INK4A or INK4B gene alterations, 95% CIs for the proportion surviving at 11 and 48 months were 0.70-0.94 and 0.45-0.78, respectively; for patients whose tumors exhibited such alterations, the 95% CIs at 11 and 47 months were 0.28-0.92 and 0.002-0.65, respectively. gous deletions and a partial allelic loss were identified as affecting exon 1␤, which specifically encodes the aminoterminal domain of p19 ARF . All tumors displaying homozygous or heterozygous p19 ARF exon 1␤ deletions had concomitant deletions of the p16 and p15 genes.
Genotypic or phenotypic alterations of TP53 were detected in 16 cases, only two of which simultaneously displayed a homozygous deletion affecting both INK4A and INK4B genes. Alterations in the MDM2 gene and/or in Mdm2 protein expression were identified in 21 tumors. Of interest, a tumor in which both TP53 and MDM2 were altered also showed LOH at the INK4A/INK4B region, but the contralateral alleles, including INK4A exon 1␤, were found to be of the wild type. Similarly, only one tumor in which concomitant pRB and INK4A alterations were identified possessed an abnormal pattern of INK4A bands, suggestive of a rearrangement. Six tumors had p53 and pRB alterations; however, none of these cases showed mutations in either the INK4A or the INK4B genes. These results suggest that additional alterations in the p53 pathway (through changes in p19 ARF ) and the pRB pathway (through changes in p16 and p15) as part of tumorigenesis of sarcomas would be unnecessary and redundant.
Coordinate inactivation of p53 and pRB appears to be an essential requirement for the genesis of most human cancers (42) (43) (44) . It has also been postulated that the loss of function of certain CKIs, mainly p16, might also lead to tumor development (32) . Even though, at the protein sequence level, p16 and p15 share 82% homology, their activities are regulated differently. p15 is an effector of transforming growth factor-␤ (TGF-␤)-induced cell cycle arrest (14) . The regulatory pathway involving p16 has not yet been well characterized; however, membrane-signaling pathways, including those mediated by TGF-␤, do not appear to be involved. A report (45) has shown that p16 accumulates in cell lines devoid of pRB, which suggests that its expression may be influenced by a transcription factor modulated by pRB. Evidence suggests that the p16/CDK4/cyclin D1/RB pathway behaves as a single mutagenic target during tumorigenesis (1-3) . Cell cycle arrest produced by p19 ARF has been shown to be dependent on p53, because cells that lack p53 do not respond to the action of p19 ARF (33) . More recently, it has been reported that p19 ARF interacts with Mdm2 protein and blocks the Mdm2-induced degradation and transactivational silencing of p53 (21, 22) .
Several studies (44, 46, 47) have reported that alterations of p53 and pRB are potentially synergistic on the proliferative activity of tumors and that they exert a cooperative negative effect on both progression and survival in certain human primary tumors. It is postulated that aberrant p53 and pRB expression deregulates cell cycle control at the G 1 checkpoint, resulting in tumor cells with reduced response to programmed cell death. The imbalance produced by enhanced proliferative activity combined with decreased apoptosis may explain the aggressive clinical course of tumors harboring both p53 and pRB alterations. The recent evidence that INK4A encodes two products that have an impact on these two suppressor pathways, p16 through the pRB pathway and p19
ARF through the p53 pathway, positions the INK4A gene at the nexus of the two most critical tumorsuppressor pathways governing neoplasia (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . Inactivation of p16 and p19 ARF in primary tumors may not be functionally equivalent to alterations in p53 and pRB expression but still might produce aggressive biologic behavior. Data from our study confirm this prediction, because adult patients affected with high-grade soft tissue sarcomas that harbor homozygous deletions of the INK4A gene had a poor clinical outcome. It is of interest that, in the cohort of sarcomas analyzed by us, there were no point mutations or methylation changes that could silence p16 alone and consequently affect the pRB, but not the p53, pathway.
In summary, recent data (21, 22, 33) provide for a ''one gene/two products/two pathways'' hypothesis that can explain the high rate of INK4A alterations in human primary cancers, as well as in a wide variety of tumor cell lines. These data also offer an answer for the tumor-prone phenotype observed in the Ink4a (32) and p19 ARF (33) knockout models, as compared with other CKIs such as p21 (48) and p27 (49) (50) (51) . Our study shows that the alteration of the INK4A and INK4B genes, particularly a coincident homozygous deletion that eliminates three important cell-growth inhibitors (p16, p19 ARF , and p15), appears to be a frequent event in adult soft tissue sarcomas. Inactivation of p16 and p19 ARF in primary tumors may not be functionally equivalent to alterations of p53 and pRB, yet it appears to produce cancers with aggressive biologic behavior. The statistically significant reduction in survival of patients bearing tumors with INK4A and INK4B gene alterations suggests that these genes may provide prognostic molecular parameters for the evaluation of patients affected by soft tissue sarcomas.
